Outset Medical (NASDAQ:OM) CEO Leslie Trigg Sells 3,437 Shares of Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 3,437 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $4.39, for a total value of $15,088.43. Following the completion of the sale, the chief executive officer directly owned 194,597 shares in the company, valued at $854,280.83. This represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Outset Medical Stock Performance

Shares of OM traded down $0.33 during midday trading on Tuesday, hitting $4.18. 143,860 shares of the stock traded hands, compared to its average volume of 129,697. Outset Medical, Inc. has a 1-year low of $3.00 and a 1-year high of $16.16. The firm has a market capitalization of $78.58 million, a PE ratio of -1.02 and a beta of 1.96. The company has a debt-to-equity ratio of 1.03, a quick ratio of 4.11 and a current ratio of 5.19. The business’s 50 day moving average price is $4.57 and its two-hundred day moving average price is $4.23.

Outset Medical (NASDAQ:OM) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.08). Outset Medical had a negative return on equity of 61.67% and a negative net margin of 63.06%.The firm had revenue of $31.64 million for the quarter, compared to the consensus estimate of $28.97 million. Equities research analysts predict that Outset Medical, Inc. will post -3.8 EPS for the current fiscal year.

Institutional Investors Weigh In On Outset Medical

Institutional investors have recently bought and sold shares of the stock. BML Capital Management LLC bought a new stake in shares of Outset Medical during the 4th quarter worth about $2,015,000. Renaissance Technologies LLC boosted its holdings in shares of Outset Medical by 391.3% in the first quarter. Renaissance Technologies LLC now owns 222,075 shares of the company’s stock valued at $853,000 after acquiring an additional 176,870 shares in the last quarter. Hsbc Holdings PLC bought a new position in shares of Outset Medical in the fourth quarter valued at approximately $46,000. BNP Paribas Financial Markets increased its stake in shares of Outset Medical by 7,013.8% during the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after acquiring an additional 2,034 shares during the period. Finally, Legal & General Group Plc acquired a new position in shares of Outset Medical during the second quarter valued at approximately $34,000.

Wall Street Analyst Weigh In

Several research firms have commented on OM. TD Cowen restated a “buy” rating on shares of Outset Medical in a research report on Friday, May 8th. Wall Street Zen raised Outset Medical from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings upgraded Outset Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $10.00.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.